872989-08-7

Upstream product

• 1002337-20-3 pentafluorophenyl (+/-)-2-(6-methoxynaphth-2-yl)propionate 
• 190970-57-1 (S)-4-phenyl-1,3-oxazolidine-2-thione 
• 771-61-9 2,3,4,5,6-pentafluorophenol 
• 22204-53-1 (2S)-2-(6-methoxy(2-naphthyl))propanoic acid 

Downstream Products

• 878194-08-2 (4R,2'S)-3-[2'-(6-methoxy-naphthalen-2-yl)propionyl]-4-phenyl-oxazolidin-2-one 
• 960210-90-6 1-phenylethyl 2-(6-methoxynaphthalen-2-yl)propionate 
• 1262241-07-5 C₂₄H₂₂N₂OS 
• 1262241-06-4 C₂₉H₂₆N₂O₂S 
• 1262241-04-2 C₂₅H₂₄N₂OS 
• 1262241-17-7 C₂₅H₂₄N₂OS 
• 1220165-16-1 (2S,4R,5S)-3-[2-(6-methoxynaphthalen-2-yl)propionyl]-4,5-diphenylimidazolidine-2-thione 

Relevant academic research and scientific papers

Efficient parallel resolution of racemic Evans' oxazolidinones using quasi-enantiomeric profens

Racemic Evans' oxazolidinones were efficiently resolved using a combination of qusi-enantiomeric profens. The levels of stereocontrol were high, giving products with predictable configurations. Georg Thieme Verlag Stuttgart.

Resolution of pentafluorophenyl active esters using (S)-4-phenyloxazolidin- 2-thione

A series of structurally related racemic pentafluorophenyl active esters were resolved using an equimolar amount of (S)-4- phenyloxazolidin-2-thione. The levels of diastereocontrol were found to be excellent (>86% de at -30% conversion).

Parallel kinetic resolution of racemic oxazolidinones using quasi-enantiomeric active esters

Racemic Evans' oxazolidinones were efficiently resolved using a combination of quasi-enantiomeric profens. The levels of stereocontrol were high, leading to products with predictable configurations.

Synthesis, characterisation and application of enantiomeric isotopomers of Evans' oxazolidinones

The synthesis of a series of enantiomerically pure deuterium-labelled isotopomeric Evans' oxazolidinones is discussed.

Oligonucleotides comprising a non-phosphate backbone linkage

One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.